clinical trial · NCT06353087
Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)
Dermatitis, AtopicDermatitisEczemaSkin DiseasesImmune System DiseasesJanus Kinase Inhibitors
brief summary
This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline characteristics.
started
Jun 19, 2024
primary completion
Jan 30, 2027
completion
Jan 30, 2027
last updated
Jul 6, 2026
official title
The Real-world Treatment Patterns and Clinical Outcomes in Moderate-to-severe Atopic Dermatitis (AD) Patients Receiving Abrocitinib
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol